Axonal dysfunction prior to neuropathy onset in type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 1, 2013, Pages 53-59

  Arnold, Ria ^a   Kwai, Natalie ^a   Lin, Cindy S Y ^a   Poynten, Ann M ^b   Kiernan, Matthew C ^c   Krishnan, Arun V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Diabetic neuropathy; Na+ K+pump; Nerve excitability; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; AXONAL DYSFUNCTION; CLINICAL ARTICLE; DIABETIC PATIENT; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NERVE EXCITABILITY; NERVE FIBER MEMBRANE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ACTION POTENTIALS; ADULT; AGED; AXONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84872228018     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2360     Document Type: Article

References (32)

1. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988; 81(2): 349-364.
2. Sima AAF. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide. J Neurol Sci 2004; 220(1-2): 133-136.
3. Sima AAF, Zhang W, Xu G, Sugimoto K, Guberski D, Yorek MA. A comparison of diabetic polyneuropathy in Type II diabetic BBZDR/Wor rats and in Type I diabetic BB/Wor rats. Diabetologia 2000; 43(6): 786-793. doi:10.1007/s001250051376.
4. Sima AA, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985; 18(1): 21-29.
5. Brismar T, Sima AA. Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: potential clamp analysis. Acta Physiol Scand 1981; 113(4): 499-506.
6. Hendriksen PH, Oey PL, Wieneke GH, Bravenboer B, Banga JD. Subclinical diabetic neuropathy: similarities between electrophysiological results of patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35(7): 690-695.
7. Loseth S, Mellgren SI, Jorde R, Lindal S, Stalberg E. Polyneuropathy in type 1 and type 2 diabetes: comparison of nerve conduction studies, thermal perception thresholds and intraepidermal nerve fibre densities. Diabetes Metab Res 2010; 26(2): 100-106.
8. Krishnan AV, Lin CS, Park SB, et al. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol 2009; 89(3): 288-313.
9. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst 2008; 13: 7-26.
10. Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clin Oncol 2009; 27(8): 1243-1249.
11. Lin CS-Y, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68(7): 862-869. doi:10.1001/archneurol.2011.137.
12. Kitano Y, Kuwabara S, Misawa S, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 2004; 56(4): 462-467.
13. Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005; 128: 1178-1187.
14. + pump dysfunction in diabetic neuropathy. Brain 2008; 131: 1209-1216.
15. Brismar T, Sima AA, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987; 21(5): 504-507.
16. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53(8): 1660-1664.
17. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23(3): 399-409.
18. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of human peripheral nerve. Brain 1996; 119(Pt 2): 439-447.
19. Bostock H, Baker M. Evidence for two types of potassium channel in human motor axons in vivo. Brain Res 1988; 462(2): 354-358.
20. Burke D. Microneurography, impulse conduction, and paresthesias. Muscle Nerve 1993; 16(10): 1025-1032.
21. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123(Pt 12): 2542-2551.
22. Misawa S, Kuwabara S, Kanai K, et al. Axonal potassium conductance and glycemic control in human diabetic nerves. Clin Neurophysiol 2005; 116: 1181-1187.
23. Bae JS, Kim OK, Kim JM, Bae JS, Kim OK, Kim JM. Altered nerve excitability in subclinical/early diabetic neuropathy: evidence for early neurovascular process in diabetes mellitus? Diabetes Res Clin Pr 2010; 91(2): 183-189.
24. Krishnan AV, Lin CS, Kiernan MC. Excitability differences in lower-limb motor axons during and after ischemia. Muscle Nerve 2005; 31(2): 205-213.
25. Kamiya H, Zhang W, Sima AA. The beneficial effects of C-peptide on diabetic polyneuropathy. Rev Diab Stud 2009; 6: 187-202.
26. Sima AAF, Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann NY Acad Sci 2006; 1084: 235-249.
27. Sima AA. C-peptide and diabetic neuropathy. Expert Opin Invest Drugs 2003; 12(9): 1471-1488.
28. Rakowski RF, Gadsby DC, De Weer P. Voltage dependence of the Na/K pump. J Membr Biol 1997; 155(2): 105-112.
29. Lehning EJ, Doshi R, Isaksson N, Stys PK, LoPachin RM. Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of the reverse sodium-calcium exchange. J Neurochem 1996; 66: 493-500.
30. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58(7): 1634-1640. doi:10.2337/db08-1771.
31. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complicat 2010; 24: 354-360.
32. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007; (4):CD004572.doi:10.1002/14651858.CD004572.pub2.